Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
Portfolio Pulse from Avi Kapoor
Jim Cramer discussed various healthcare and technology stocks on CNBC's 'Mad Money Lightning Round'. He recommended staying with Realty Income (O), called ImmunoGen (IMGN) a property of AbbVie (ABBV), and labeled GE HealthCare Technologies (GEHC) as 'ridiculously cheap'. He was not a buyer of Ramaco Resources (METC) and expressed uncertainty about Bitfarms (BITF) and TKO Group Holdings (TKO). Cramer was positive about Arm Holdings (ARMH) and neutral about Micron Technology (MU), but found Coherent Corp. (COHR) too expensive and is not a supporter of Teva Pharmaceutical (TEVA).
January 08, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie was mentioned in relation to owning ImmunoGen, which could reflect positively on AbbVie's portfolio.
The association with ImmunoGen could be seen as a positive expansion of AbbVie's portfolio, potentially leading to a slight positive impact on its stock.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Cramer was positive about Arm Holdings, particularly praising CEO Rene Haas, which could lead to increased investor interest.
Cramer's positive remarks about Arm Holdings and its CEO could boost investor confidence and potentially lead to a rise in the stock's price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Cramer highlighted GE HealthCare Technologies as 'ridiculously cheap' and praised its performance, suggesting a strong buy signal.
Cramer's strong positive sentiment towards GE HealthCare Technologies, calling it cheap and performing well, is likely to influence investors and could lead to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Cramer believes Micron Technology can maintain its current price or return to higher levels, indicating a neutral to slightly positive outlook.
Cramer's comment on Micron Technology suggests a neutral to slightly positive short-term impact, as he believes the stock can either tread water or increase in value.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Jim Cramer recommended staying with Realty Income, indicating a positive outlook.
Cramer's endorsement as a steady investment could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Cramer referred to ImmunoGen as a property of AbbVie, suggesting it may no longer be an independent investment consideration.
The mention of ImmunoGen as AbbVie's property implies that its individual performance may be less relevant to investors, potentially neutralizing its short-term impact.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50
NEUTRAL IMPACT
Cramer's uncertainty about how to value TKO Group Holdings could reflect investor confusion, potentially affecting the stock's performance.
Cramer's lack of understanding on how to value TKO Group Holdings may lead to investor indecision, likely resulting in a neutral short-term impact on the stock.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 60
NEGATIVE IMPACT
Cramer's characterization of Bitfarms as 'speculative' could lead to investor caution, potentially impacting the stock negatively.
Cramer's speculative tag on Bitfarms may cause investors to be wary, which could result in a decrease in the stock's short-term price.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 70
NEGATIVE IMPACT
Cramer's view of Coherent Corp. as 'a little too expensive' could deter investors, potentially impacting the stock negatively.
Cramer's opinion that Coherent Corp. is overvalued may lead to a negative perception among investors, possibly resulting in a short-term decrease in stock price.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 70
NEGATIVE IMPACT
Cramer's decision to not buy Ramaco Resources indicates a negative sentiment that could be echoed by investors.
Cramer's lack of interest in Ramaco Resources may suggest to investors that the stock is not a good buy, which could lead to a short-term negative impact on its price.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Cramer's lack of support for Teva Pharmaceutical could influence investors negatively, potentially affecting the stock's performance.
Cramer's disapproval of Teva Pharmaceutical could lead to decreased investor interest and possibly a decline in the stock price in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70